GlassScriptPhysician profile
Dana L Demoss
NPI 1346241130
$75,813.37
in general payments reported to CMS, 2019-2025
61 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,805 · 2022: $20K · 2023: $11K · 2024: $19K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $9,285 · Travel and Lodging: $7,475 · Consulting Fee: $1,533 · Education: $56.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,050.00 |
| Food and Beverage | $9,284.75 |
| Travel and Lodging | $7,474.74 |
| Consulting Fee | $1,532.50 |
| Education | $56.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $61,559.90 | 2021-2025 | Lynparza, Enhertu, Calquence |
| Glaxosmithkline, LLC. | $4,757.89 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $2,058.44 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $530.05 | 2023-2025 | Rybrevant, Darzalex, Talvey |
| Regeneron Healthcare Solutions, INC. | $511.69 | 2022-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $470.11 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $436.15 | 2021-2025 | Opdualag, Opdivo |
| Seagen INC. | $392.34 | 2021-2023 | Tukysa, Adcetris |
| Daiichi Sankyo INC. | $360.83 | 2022-2025 | Enhertu |
| Celgene Corporation | $290.81 | 2022-2025 | Reblozyl, Breyanzi |
| Myriad Genetic Laboratories, INC. | $278.34 | 2024 | Mychoice Cdx, Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $259.48 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $241.29 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $233.85 | 2023-2025 | Fotivda |
| Eisai INC. | $228.29 | 2023-2025 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $195.58 | 2023-2025 | |
| Genzyme Corporation | $193.36 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.15 | 2022-2025 | Iclusig, Fruzaqla, Alunbrig |
| Tersera Therapeutics LLC | $150.76 | 2022-2025 | Zoladex, Xermelo |
| Abbvie INC. | $145.12 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $123.59 | 2022 | |
| Alexion Pharmaceuticals, INC. | $121.82 | 2023-2024 | Ultomiris |
| Immunogen, INC. | $120.59 | 2023 | Elahere |
| Incyte Corporation | $118.98 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Kite Pharma, INC. | $116.34 | 2024 | |
| Puma Biotechnology, INC. | $104.99 | 2022-2025 | |
| Astellas Pharma US INC | $102.36 | 2023-2025 | Vyloy, Xtandi, Xospata |
| Pfizer INC. | $95.70 | 2023-2025 | |
| Lilly USA, LLC | $94.15 | 2023-2025 | Verzenio, Retevmo, Jaypirca |
| Emd Serono, INC. | $76.96 | 2023-2025 | Bavencio |
| Exelixis INC. | $73.95 | 2025 | Cabometyx |
| Pharmaessentia USA Corporation | $69.68 | 2023-2024 | Besremi |
| Sun Pharmaceutical Industries INC. | $69.67 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $66.90 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Gilead Sciences, INC. | $65.74 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $59.58 | 2024 | Cosela, Monoferric |
| Sobi, INC | $57.11 | 2025 | |
| Genentech USA, INC. | $50.97 | 2023-2024 | Venclexta, Tecentriq, Phesgo |
| Iovance Biotherapeutics, INC. | $50.89 | 2025 | Amtagvi |
| Genmab U.S., INC. | $49.55 | 2024-2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $45.22 | 2023 | Imbruvica |
| Blueprint Medicines Corporation | $45.08 | 2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.63 | 2024-2025 | Gilotrif |
| Amgen INC. | $41.02 | 2023 | Kyprolis |
| G1 Therapeutics, INC. | $40.48 | 2022-2023 | Cosela |
| Morphosys, US INC. | $38.70 | 2023 | Monjuvi |
| Mirati Therapeutics, INC. | $38.69 | 2023-2024 | Krazati |
| Array Biopharma INC | $37.57 | 2022-2024 | Lorbrena, Xalkori, Braftovi |
| Adc Therapeutics America, INC. | $35.87 | 2023-2025 | |
| Stemline Therapeutics INC. | $34.82 | 2024-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $30.65 | 2024-2025 | Orgovyx |
| Taiho Oncology, INC. | $26.50 | 2024 | |
| Shield Therapeutics INC | $22.28 | 2025 | |
| Cycle Pharmaceuticals INC | $21.67 | 2025 | Phyrago |
| Coherus Oncology, INC. | $21.52 | 2024 | |
| Geron Corporation | $21.44 | 2025 | Rytelo |
| Macrogenics, INC. | $20.55 | 2023 | |
| Karyopharm Therapeutics INC. | $19.99 | 2025 | Xpovio |
| Beigene USA, INC. | $19.15 | 2025 | Tevimbra |
| Cti Biopharma Corp. | $19.08 | 2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $18.51 | 2024 | Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Demoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.